Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-06f9b891f2158becb7dcf14e44abf883",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-06f9b891f2158becb7dcf14e44abf883",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-06f9b891f2158becb7dcf14e44abf883",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-06f9b891f2158becb7dcf14e44abf883\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-06f9b891f2158becb7dcf14e44abf883</b></p><a name=\"composition-en-06f9b891f2158becb7dcf14e44abf883\"> </a><a name=\"hccomposition-en-06f9b891f2158becb7dcf14e44abf883\"> </a><a name=\"composition-en-06f9b891f2158becb7dcf14e44abf883-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/08/492/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - roactemra</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/08/492/001"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp06f9b891f2158becb7dcf14e44abf883"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - roactemra",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet:</p><ol type=\"1\"><li>What RoActemra is and what it is used for</li><li>What you need to know before you are given RoActemra</li><li>How RoActemra is given</li><li>Possible side effects</li><li>How to store RoActemra</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What roactemra is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What roactemra is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>RoActemra contains the active substance tocilizumab, which is a protein made from specific immune cells (monoclonal antibody), that blocks the action of a specific protein (cytokine) called interleukin-6. This protein is involved in inflammatory processes of the body, and blocking it can reduce the inflammation in your body. RoActemra helps to reduce symptoms such as pain and swelling in your joints and can also improve your performance of daily tasks. RoActemra has been shown to slow the damage to the cartilage and bone of the joints caused by the disease and to improve your ability to do normal daily activities.</p><ul><li><p>RoActemra is used to treat adults with moderate to severe active rheumatoid arthritis (RA), an autoimmune disease, if previous therapies did not work well enough. RoActemra is usually given in combination with methotrexate. However, RoActemra can be given alone if your doctor determines that methotrexate is inappropriate.</p></li><li><p>RoActemra can also be used to treat adults who have not had previous methotrexate treatment if they have severe, active and progressive rheumatoid arthritis.</p></li><li><p>RoActemra is used to treat children with sJIA. RoActemra is used for children aged 2 years and over who have active systemic juvenile idiopathic arthritis (sJIA), an inflammatory disease that causes pain and swelling in one or more joints as well as fever and rash. RoActemra is used to improve the symptoms of sJIA and can be given in combination with methotrexate or alone.</p></li><li><p>RoActemra is used to treat children with pJIA. RoActemra is used for children aged 2 years and over with active polyarticular juvenile idiopathic arthritis (pJIA), an inflammatory disease that causes pain and swelling in one or more joints. RoActemra is used to improve the symptoms of pJIA and can be given in combination with methotrexate or alone.</p></li><li><p>RoActemra is used to treat adults and children aged 2 years and over with severe or life- threatening cytokine release syndrome (CRS), a side-effect in patients treated with chimeric antigen receptor (CAR) T-cell therapies used to treat certain types of cancer.</p></li><li><p>RoActemra is used to treat adults with coronavirus disease 2019 (COVID-19), receiving systemic corticosteroids and requiring supplemental oxygen or mechanical ventilation.</p></li></ul></div>"
}
},
{
"title" : "2. What you need to know before you take roactemra",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take roactemra"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>You are not to be given RoActemra</p><ul><li>if you are allergic to tocilizumab or any of the other ingredients of this medicine (listed in Section 6).</li><li>if you have an active, severe infection. If any of these applies to you, tell the doctor or nurse giving you the infusion.</li></ul><p>Warnings and precautions<br/>Talk to your doctor or nurse before you are given RoActemra.</p><ul><li><p>If you experience allergic reactions such as chest tightness, wheezing, severe dizziness or light-headedness, swelling of the lips or skin rash during or after the infusion, then tell your doctor immediately.</p></li><li><p>If you have any kind of infection, short- or long-term, or if you often get infections. Tell your doctor immediately if you feel unwell. RoActemra can reduce your body s ability to respond to infections and may make an existing infection worse or increase the chance of getting a new infection.</p></li><li><p>If you have had tuberculosis, tell your doctor. Your doctor will check for signs and symptoms of tuberculosis before starting RoActemra. If symptoms of tuberculosis (persistent cough, weight loss, listlessness, mild fever), or any other infection appear during or after therapy tell your doctor immediately.</p></li><li><p>If you have had intestinal ulcers or diverticulitis, tell your doctor. Symptoms would include abdominal pain and unexplained changes in bowel habits with a fever.</p></li><li><p>If you have liver disease, tell your doctor. Before you use RoActemra, your doctor may do a blood test to measure your liver function.</p></li><li><p>If any patient has recently been vaccinated (either adult or child), or is planning a vaccination, tell your doctor. All patients, especially children, should be up-to-date with all their vaccinations before they start treatment with RoActemra, unless urgent treatment initiation is required. Certain types of vaccines should not be used while receiving RoActemra.</p></li><li><p>If you have cancer, tell your doctor. Your doctor will have to decide if you can still be given RoActemra.</p></li><li><p>If you have cardiovascular risk factors such as raised blood pressure and raised cholesterol levels, tell your doctor. These factors need to be monitored while receiving RoActemra.</p></li><li><p>If you have moderate to severe kidney function problems, your doctor will monitor you.</p></li><li><p>If you have persistent headaches.</p></li></ul><p>Your doctor will perform blood tests before you are given RoActemra, and during your treatment, to determine if you have a low white blood cell count, low platelet count or high liver enzymes.</p><p>Children and adolescents RoActemra is not recommended for use in children under 2 years of age.</p><p>If a child has a history of macrophage activation syndrome, (activation and uncontrolled proliferation of specific blood cells), tell your doctor. Your doctor will have to decide if they can still be given RoActemra.</p><p>Other medicines and RoActemra Tell your doctor if you are taking any other medicines (or your child is, if they are the patient), or have recently taken any. This includes medicines obtained without a prescription. RoActemra can affect the way some medicines work, and the dose of these may require adjustment. If you are using medicines containing any of the following active substances, tell your doctor:</p><ul><li>methylprednisolone, dexamethasone, used to reduce inflammation</li><li>simvastatin or atorvastatin, used to reduce cholesterol levels</li><li>calcium channel blockers (e.g. amlodipine), used to treat raised blood pressure</li><li>theophylline, used to treat asthma</li><li>warfarin or phenprocoumon, used as a blood thinning agents</li><li>phenytoin, used to treat convulsions</li><li>ciclosporin, used to suppress your immune system during organ transplants</li><li>benzodiazepines (e.g. temazepam), used to relieve anxiety.</li></ul><p>Due to lack of clinical experience, RoActemra is not recommended for use with other biological medicines for the treatment of RA, sJIA or pJIA.</p><p>Pregnancy, breast-feeding and fertility RoActemra is not to be used in pregnancy unless clearly necessary. Talk to your doctor if you are pregnant, may be pregnant, or intend to become pregnant.</p><p>Women of childbearing potential must use effective contraception during and up to 3 months after treatment.</p><p>Stop breast-feeding if you are to be given RoActemra, and talk to your doctor. Leave a gap of at least 3 months after your last treatment before you start breast-feeding. It is not known whether RoActemra is passed into breast milk.</p><p>The data available so far does not suggest any effect on fertility from this treatment.</p><p>Driving and using machines This medicine can cause dizziness. If you feel dizzy, do not drive or use machines.</p><p>RoActemra contains sodium This medicine contains 26.55 mg sodium per maximum dose of 1200 mg. Take this into account if you are on a low-sodium diet. However, doses below 1025 mg of this medicine contain less than 23 mg sodium, so they are virtually sodium free.</p></div>"
}
},
{
"title" : "3. How to take roactemra",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take roactemra"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This medicine is subject to restricted medical prescription by your doctor.</p><p>RoActemra will be given to you as a drip into a vein, by a doctor or a nurse. They will dilute the solution, set up the intravenous infusion and monitor you during and after the treatment.</p><p>Adult patients with RA The usual dose of RoActemra is 8 mg per kg of body weight. Depending on your response, your doctor may decrease your dose to 4 mg/kg then increase back to 8 mg/kg when appropriate.</p><p>Adults will be given RoActemra once every 4 weeks through a drip in the vein (intravenous infusion) over one hour.</p><p>Children with sJIA (aged 2 and over) The usual dose of RoActemra depends on your weight.</p><ul><li>If you weigh less than 30 kg: the dose is 12 mg for every kilogram of body weight</li><li>If you weigh 30 kg or more: the dose is 8 mg for every kilogram of body weight The dose is calculated based on your body weight at each administration.</li></ul><p>Children with sJIA will be given RoActemra once every 2 weeks through a drip in the vein (intravenous infusion) over one hour.</p><p>Children with pJIA (aged 2 and over) The usual dose of RoActemra depends on your weight.</p><ul><li>If you weigh less than 30 kg: the dose is 10mg for every kilogram of body weight</li><li>If you weigh 30 kg or more: the dose is 8 mg for every kilogram of body weight<br/>The dose is calculated based on your body weight at each administration.</li></ul><p>Children with pJIA will be given RoActemra once every 4 weeks through a drip in the vein (intravenous infusion) over one hour.</p><p>Patients with CRS The usual dose of RoActemra is 8 mg for every kg of body weight if you weigh 30 kg or more.<br/>The dose is 12 mg for every kg of body weight if you weigh less than 30 kg.<br/>RoActemra can be given alone or in combination with corticosteroids.</p><p>Patients with COVID-The usual dose of RoActemra is 8 mg for every kg of body weight. A second dose may be required.</p><p>If you are given more RoActemra than you should Since RoActemra is given by a doctor or nurse, it is unlikely that you will be given too much. However, if you are worried, talk to your doctor.</p><p>If you miss a dose of RoActemra Since RoActemra is given by a doctor or nurse, it is unlikely that you will miss a dose. However, if you are worried, talk to your doctor or nurse.</p><p>If you stop being given RoActemra You should not stop using RoActemra without discussing with your doctor first.</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, RoActemra can cause side effects, although not everybody gets them. Side effects could occur at least up to 3 months after your last dose of RoActemra.</p><p>Possible serious side effects: tell a doctor straight away. These are common: they may affect up to 1 in every 10 users</p><p>Allergic reactions during or after infusion:</p><ul><li>difficulty with breathing, chest tightness or light-headedness</li><li>rash, itching, hives, swelling of the lips, tongue or face</li></ul><p>If you notice any of these, tell your doctor immediately.</p><p>Signs of serious infections</p><ul><li>fever and chills</li><li>mouth or skin blisters</li><li>stomach ache</li></ul><p>Signs and symptoms of liver toxicity These may affect up to 1 in every 1000 users</p><ul><li>tiredness</li><li>abdominal pain</li><li>jaundice (yellow discolouration of skin or eyes)</li></ul><p>If you notice any of these, tell your doctor as soon as possible.</p><p>Very common side effects:<br/>These may affect more than 1 in every 10 users</p><ul><li>upper respiratory tract infections with typical symptoms such as cough, blocked nose, runny nose, sore throat and headache</li><li>high blood fat (cholesterol) levels</li></ul><p>Common side effects:<br/>These may affect up to 1 in every 10 users</p><ul><li>lung infection (pneumonia)</li><li>shingles (herpes zoster)</li><li>cold sores (oral herpes simplex), blisters</li><li>skin infection (cellulitis) sometimes with fever and chills</li><li>rash and itching, hives</li><li>allergic (hypersensitivity) reactions</li><li>eye infection (conjunctivitis)</li><li>headache, dizziness, high blood pressure</li><li>mouth ulcers, stomach pain</li><li>fluid retention (oedema) in the lower legs, weight increase</li><li>cough, shortness of breath</li><li>low white blood cell counts shown by blood tests (neutropenia, leucopenia)</li><li>abnormal liver function tests (increased transaminases)</li><li>increased bilirubin shown by blood tests</li><li>low fibrinogen levels in the blood (a protein involved in blood clotting)</li></ul><p>Uncommon side effects:<br/>These may affect up to 1 in every 100 users</p><ul><li>diverticulitis (fever, nausea, diarrhoea, constipation, stomach pain)</li><li>red swollen areas in the mouth</li><li>high blood fat (triglycerides)</li><li>stomach ulcer</li><li>kidney stones</li><li>underactive thyroid</li></ul><p>Rare side effects: These may affect up to 1 in every 1,000 users</p><ul><li>Stevens-Johnson syndrome (skin rash, which may lead to severe blistering and peeling of the skin)</li><li>Fatal Allergic Reactions (Anaphylaxis [fatal])</li><li>inflammation of the liver (hepatitis), jaundice</li></ul><p>Very rare side effects: These may affect up to 1 in every 10,000 users</p><ul><li>low counts for white blood cells, red blood cells and platelets in blood tests</li><li>liver failure</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>Children with sJIA<br/>In general, side effects in sJIA patients were of a similar type to those in adults with RA. Some side effects were seen more often: inflamed nose and throat, diarrhoea, lower white blood cell counts and higher liver enzymes.</p><p>Children with pJIA<br/>In general, side effects in pJIA patients were of a similar type to those in adults with RA. Some side effects were seen more often: inflamed nose and throat, headache, feeling sick (nausea) and lower white blood cell counts.</p></div>"
}
},
{
"title" : "5. How to store roactemra",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store roactemra"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep RoActemra out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton.</p><p>Store in a refrigerator (2 C - 8 C). Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What RoActemra contains</p><ul><li>The active substance is tocilizumab.</li></ul><p>Each 4 mL vial contains 80 mg tocilizumab (20 mg/mL).</p><p>Each 10 mL vial contains 200 mg tocilizumab (20 mg/mL).</p><p>Each 20 mL vial contains 400 mg tocilizumab (20 mg/mL).</p><ul><li>The other ingredients are sucrose, polysorbate 80, disodium phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate and water for injections.</li></ul><p>What RoActemra looks like and contents of the pack RoActemra is a concentrate for solution for infusion. The concentrate is a clear to opalescent, colourless to pale yellow liquid. RoActemra is supplied as vials containing 4 mL, 10 mL and 20 mL concentrate for solution for infusion. Pack size of 1 and 4 vials. Not all pack sizes may be marketed. Marketing Authorisation Holder Roche Registration GmbH<br/>Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen Germany</p><p>Manufacturer Roche Pharma AG Emil-Barell-Str. 1 D-79639 Grenzach-Wyhlen Germany</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien N.V. Roche S.A. T l/Tel: +32 (0) 2 525 82 Luxembourg/Luxemburg (Voir/siehe Belgique/Belgien)</p><p>: +359 2 818 44 Magyarorsz g Roche (Magyarorsz g) Kft. Tel: +36 - 1 279 4 esk republika Roche s. r. o. Tel: +420 - 2 20382Malta<br/>(See Ireland)</p><p>Danmark Roche Pharmaceuticals A/S Tlf: +45 - 36 39 99 Nederland Roche Nederland B.V. Tel: +31 (0) 348 438Deutschland Roche Pharma AG Tel: +49 (0) 7624 oder Chugai Pharma Europe<br/>Zweigniederlassung Deutschland Tel: +49 (0) 69 663000 0</p><p>Norge Roche Norge AS Tlf: +47 - 22 78 90 Eesti Roche Eesti O<br/>Tel: + 372 - 6 177 sterreich Roche Austria GmbH Tel: +43 (0) 1 27<br/>Roche (Hellas) A.E.<br/>: +30 210 61 66 Polska Roche Polska Sp.z o.o. Tel: +48 - 22 345 18 Espa a Roche Farma S.A. Tel: +34 - 91 324 81 Portugal Roche Farmac utica Qu mica, Lda Tel: +351 - 21 425 70 France Roche T l: +33 (0) 1 47 61 40 ou Chugai Pharma France T l: +33 (0) 1 56 37 05 Hrvatska Roche d.o.o Tel: +385 1 47 22 Rom nia Roche Rom nia S.R.L. Tel: +40 21 206 47 Ireland Roche Products (Ireland) Ltd. Tel: +353 (0) 1 469 0Slovenija Roche farmacevtska dru ba d.o.o. Tel: +386 - 1 360 26 sland<br/>Roche Pharmaceuticals A/S c/o Icepharma hf S mi: +354 540 8Slovensk republika<br/>Roche Slovensko, s.r.o. Tel: +421 - 2 52638Italia Roche S.p.A. Tel: +39 - 039 2Suomi/Finland Roche Oy<br/>Puh/Tel: +358 (0) 10 554 K<br/>. . & . : +357 - 22 76 62 Sverige Roche AB Tel: +46 (0) 8 726 1Latvija Roche Latvija SIA Tel: +371 - 6 7039United Kingdom (Northern Ireland) Roche Products (Ireland) Ltd. Tel: +44 (0) 1707 366or Chugai Pharma UK Ltd. Tel: +44 (0) 208 987 5Lietuva UAB Roche Lietuva<br/>Tel: +370 5 2546This leaflet was last revised in</p><p>Other sources of information Detailed information on this medicine is available on the European Medicines Agency website: <a href=\"http://www.ema.europa.eu/\">http://www.ema.europa.eu/</a>.</p><p>The following information is intended for healthcare professionals only:</p><p>Instructions for dilution prior to administration Parenteral medicinal products should be inspected visually for particulate matter or discolouration prior to administration. Only solutions which are clear to opalescent, colourless to pale yellow and free of visible particles should be diluted. Use a sterile needle and syringe to prepare RoActemra.</p><p>RA, COVID-19 and CRS adult patients ( 30 kg) Withdraw a volume of sterile, non-pyrogenic sodium chloride 9 mg/mL (0.9%) solution for injection from a 100 mL infusion bag, equal to the volume of RoActemra concentrate required for the patients dose, under aseptic conditions. The required amount of RoActemra concentrate (0.4 mL/kg) should be withdrawn from the vial and placed in the 100 mL infusion bag. This should be a final volume of 100 mL. To mix the solution, gently invert the infusion bag to avoid foaming.</p><p>Use in the paediatric population</p><p>sJIA, pJIA and CRS patients 30 kg Withdraw a volume of sterile, non-pyrogenic sodium chloride 9 mg/mL (0.9%) solution for injection from a 100 mL infusion bag, equal to the volume of RoActemra concentrate required for the patients dose, under aseptic conditions. The required amount of RoActemra concentrate (0.4 mL/kg) should be withdrawn from the vial and placed in the 100 mL infusion bag. This should be a final volume of 100 mL. To mix the solution, gently invert the infusion bag to avoid foaming.</p><p>sJIA and CRS patients < 30 kg Withdraw a volume of sterile, non-pyrogenic sodium chloride 9 mg/mL (0.9%) solution for injection from a 50 mL infusion bag, equal to the volume of RoActemra concentrate required for the patients dose, under aseptic conditions. The required amount of RoActemra concentrate (0.6 mL/kg) should be withdrawn from the vial and placed in the 50 mL infusion bag. This should be a final volume of 50 mL. To mix the solution, gently invert the infusion bag to avoid foaming.</p><p>pJIA patients < 30 kg Withdraw a volume of sterile, non-pyrogenic sodium chloride 9 mg/mL (0.9%) solution for injection from a 50 mL infusion bag, equal to the volume of RoActemra concentrate required for the patients dose, under aseptic conditions. The required amount of RoActemra concentrate (0.5 mL/kg) should be withdrawn from the vial and placed in the 50 mL infusion bag. This should be a final volume of 50 mL. To mix the solution, gently invert the infusion bag to avoid foaming.</p><p>RoActemra is for single-use only.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>Package leaflet: Information for the user</p><p>RoActemra 162 mg solution for injection in pre-filled syringe tocilizumab</p><p>Read all of this leaflet carefully before you start using this medicine because it contains<br/>important information for you.</p><ul><li>Keep this leaflet. You may need to read it again.</li><li>If you have any further questions, ask your doctor, pharmacist or nurse.</li><li>This medicine has been prescribed for you only. Do not pass it onto others. It may harm them even if their signs of illness are the same as yours.</li><li>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. In addition to this leaflet, you will be given a Patient Alert Card, which contains important safety information that you need to be aware of before and during treatment with RoActemra.</li></ul></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp06f9b891f2158becb7dcf14e44abf883",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp06f9b891f2158becb7dcf14e44abf883",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp06f9b891f2158becb7dcf14e44abf883\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp06f9b891f2158becb7dcf14e44abf883</b></p><a name=\"mp06f9b891f2158becb7dcf14e44abf883\"> </a><a name=\"hcmp06f9b891f2158becb7dcf14e44abf883\"> </a><a name=\"mp06f9b891f2158becb7dcf14e44abf883-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/08/492/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: RoActemra 20 mg/mL concentrate for solution for infusion.</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/08/492/001"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "RoActemra 20 mg/mL concentrate for solution for infusion.",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
